Genoa pharmacist discussing medications with clinic partner
Genoa pharmacist discussing medications with clinic partner
  • Behavioral Health
  • Clinical Insights
  • Treatment

Cobenfy™: 5 things to know about the new schizophrenia treatment option

Oct 1st, 2024
Want to learn more about Cobenfy? Save your seat for Genoa’s webinar on Oct. 9 here.

Staying on top of new medication therapy options for your consumers living with schizophrenia can be difficult. Learn how the new FDA-approved medication, Cobenfy – approved on September 26, 2024 – can help support the people you serve.

1. Cobenfy is the first in a new class of antipsychotic medications targeting muscarinic receptors and an alternative to D2 dopamine receptor antagonists not associated with the adverse effects of EPS, weight gain, or somnolence.

2. Cobenfy (xanomeline-trospium chloride) is a twice-daily oral medication with a novel mechanism of action.

3. Cobenfy combines xanomeline and trospium. Xanomeline targets the central nervous system (CNS) muscarinic receptors (M1 and M4 receptor agonist) while trospium is a muscarinic receptor antagonist working peripherally to reduce side effects.

4. While traditional antipsychotic medications primarily target dopamine receptors in the brain, Cobenfy preferentially activates the M1 and M4 neuroreceptors.

5. In data from the EMERGENT trial, Cobenfy demonstrated effectiveness in reducing schizophrenia symptoms with minimal adverse events. The most common side effects noted were gastrointestinal, such as nausea, vomiting, constipation and diarrhea.

      For more information or questions on availability, contact your local Genoa pharmacy team.

      Hear from industry experts

      Join Genoa’s drug trends webinar on Wednesday, October 9, at 12 p.m. CT to learn more about 2024 drug approvals, tips for incorporating them into treatment plans and trends for 2025.

      About the author

      Kim Cordova, PharmD, serves as the director of Genoa’s procurement team, overseeing clinical procurement and trade relations. She plays a key role in ensuring the availability of pharmaceutical products and supports Genoa’s pharmacy teams to ensure they are well-equipped to deliver the highest quality care to the communities they serve.

      For general information on Cobenfy: https://www.cobenfy.com/home.html

      This information was accurate at the time of posting.

      Recent Posts


      Partner with Genoa
      • Partnering with Genoa
      • People-first Pharmacy Care
      Health equity and vaccine acess: Genoa’s commitment to care

      The goal of health equity is to ensure that every person, regardless of their background or circumstances, has access to the health care they need. Unfortunately, many communities face significant...

      Genoa pharmacist discussing medications with clinic partner
      • Behavioral Health
      • Clinical Insights
      • Treatment
      Cobenfy™: 5 things to know about the new schizophrenia treatment option

      Want to learn more about Cobenfy? Save your seat for Genoa’s webinar on Oct. 9 here. Staying on top of new medication therapy options for your consumers living with schizophrenia...

      • Consumer Stories
      • Partnering with Genoa
      • People-first Pharmacy Care
      1,000 consumers stay on their treatment because one Genoa Healthcare pharmacy team stepped up

      After a large long-term care pharmacy in Anchorage, Alaska unexpectedly announced its closure earlier this year, patients across the state were left unsure of where they could get the medications...

      • Art Celebration
      Healing through art: Genoa’s annual Art Celebration

      Each year, the Genoa Healthcare® Art Celebration celebrates consumers, their talents and the healing power of art. The 2024 Art Celebration received a record number of over 1,600 submissions. That’s...